Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

The erectile dysfunction pill company Hims will be worth $1 billion

Some investors balked at the price tag for the direct-to-consumer men’s health brand.

The year-old men’s health company Hims — which sells millennials hair-loss products and erectile dysfunction medication — is soon to be valued at $1 billion in a new round of fundraising, Recode has learned.

Hims is finalizing a $100 million round of new money, according to people familiar with the matter. The company is one of the buzzier digital brands in the world of e-commerce, already taking in about $100 million in previous cash and expanding in November into the women’s health business with a new line of products called Hers.

But it took the company quite a while to reach the $1 billion price it has been talking with investors on for several months, with some of them balking at the valuation. The company has basically been looking for new cash since it closed its last round of money last summer.

The lead investor is a late-stage investing firm that has not previously backed the company, one source said, but its identity couldn’t be immediately learned. Hims declined to comment. CNBC reported in August about Hims’ early approaches to investors.

Hims is hitting the vaunted $1 billion valuation territory with speed: The business only launched in November 2017. In addition to competing with legacy sellers of Viagra and Rogaine, Hims is battling for investor support with another direct-to-consumer men’s health brand, Roman.

Both companies are hoping to create businesses that take advantage of the stigma surrounding men’s health by removing middlemen like pharmacies and doctors. Hims founder Andrew Dudum has tried to pitch his company as not merely a brand but as a health care company with loyal patient relationships.

Still, one challenge for Hims, given its rapid cash-grabbing, will be for it to heed its founder’s words.

“You hear a lot of this: Raise a ton of money, spend it on marketing, get a bunch of customers and build really fast. I’m not convinced that that’s the best way to build a long-lasting business,” Dudum said last month. “A lot of brands being created could spend more time thinking about this stuff because the pump-and-dump of venture capital is not sustainable.”

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh